| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Decision Support Systems, Clinical | 34 | 2020 | 63 | 9.340 |
Why?
|
| Oocytes | 24 | 2015 | 45 | 6.540 |
Why?
|
| Meiosis | 21 | 2015 | 33 | 5.040 |
Why?
|
| Mass Screening | 16 | 2020 | 256 | 3.920 |
Why?
|
| Parents | 16 | 2021 | 151 | 3.630 |
Why?
|
| Pediatrics | 20 | 2019 | 156 | 3.370 |
Why?
|
| Primary Health Care | 17 | 2021 | 232 | 3.100 |
Why?
|
| Vaccination | 9 | 2019 | 156 | 2.550 |
Why?
|
| Child | 54 | 2021 | 2430 | 2.490 |
Why?
|
| AMP-Activated Protein Kinases | 14 | 2015 | 33 | 2.420 |
Why?
|
| Child, Preschool | 34 | 2019 | 1233 | 2.130 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 9 | 2018 | 37 | 2.050 |
Why?
|
| Female | 92 | 2019 | 19935 | 1.940 |
Why?
|
| Papillomavirus Vaccines | 6 | 2019 | 43 | 1.930 |
Why?
|
| Humans | 125 | 2021 | 32262 | 1.820 |
Why?
|
| Referral and Consultation | 7 | 2019 | 137 | 1.730 |
Why?
|
| Depression | 10 | 2019 | 425 | 1.680 |
Why?
|
| Physicians | 5 | 2018 | 163 | 1.680 |
Why?
|
| Electronic Health Records | 10 | 2019 | 179 | 1.580 |
Why?
|
| Attitude to Computers | 4 | 2020 | 16 | 1.560 |
Why?
|
| Urinary Tract Infections | 5 | 2020 | 42 | 1.550 |
Why?
|
| Attitude of Health Personnel | 7 | 2018 | 183 | 1.530 |
Why?
|
| Child Development | 4 | 2019 | 45 | 1.490 |
Why?
|
| Male | 65 | 2019 | 19429 | 1.490 |
Why?
|
| Medical Records Systems, Computerized | 11 | 2013 | 37 | 1.400 |
Why?
|
| Adolescent | 33 | 2021 | 3509 | 1.370 |
Why?
|
| Decision Support Techniques | 8 | 2019 | 129 | 1.350 |
Why?
|
| Cost-Benefit Analysis | 12 | 2019 | 191 | 1.330 |
Why?
|
| Developmental Disabilities | 4 | 2014 | 16 | 1.320 |
Why?
|
| Infant | 23 | 2019 | 1010 | 1.250 |
Why?
|
| Mice | 23 | 2015 | 2571 | 1.240 |
Why?
|
| Papillomavirus Infections | 5 | 2019 | 70 | 1.230 |
Why?
|
| Indiana | 21 | 2019 | 26 | 1.190 |
Why?
|
| Attitude to Health | 4 | 2017 | 137 | 1.190 |
Why?
|
| Neonatal Screening | 6 | 2013 | 11 | 1.170 |
Why?
|
| Preventive Health Services | 6 | 2015 | 39 | 1.150 |
Why?
|
| User-Computer Interface | 12 | 2018 | 54 | 1.110 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2019 | 56 | 1.090 |
Why?
|
| Reminder Systems | 7 | 2015 | 23 | 1.060 |
Why?
|
| Practice Guidelines as Topic | 10 | 2016 | 395 | 1.060 |
Why?
|
| Multienzyme Complexes | 6 | 2007 | 19 | 1.050 |
Why?
|
| Communication | 2 | 2019 | 128 | 1.040 |
Why?
|
| Cumulus Cells | 6 | 2015 | 6 | 1.040 |
Why?
|
| Protein-Serine-Threonine Kinases | 6 | 2007 | 49 | 1.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2017 | 316 | 1.000 |
Why?
|
| Ovarian Follicle | 5 | 2015 | 36 | 0.980 |
Why?
|
| Aminoimidazole Carboxamide | 9 | 2013 | 9 | 0.980 |
Why?
|
| Infant, Newborn | 16 | 2019 | 666 | 0.920 |
Why?
|
| Mice, Inbred C57BL | 16 | 2013 | 792 | 0.870 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 2 | 2015 | 3 | 0.870 |
Why?
|
| Guideline Adherence | 6 | 2013 | 109 | 0.860 |
Why?
|
| Artificial Intelligence | 5 | 2015 | 64 | 0.860 |
Why?
|
| Animals | 27 | 2018 | 8196 | 0.850 |
Why?
|
| Ribonucleotides | 9 | 2013 | 10 | 0.840 |
Why?
|
| Algorithms | 11 | 2013 | 536 | 0.830 |
Why?
|
| Bayes Theorem | 5 | 2013 | 82 | 0.830 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 2 | 2014 | 3 | 0.820 |
Why?
|
| Parenting | 4 | 2021 | 23 | 0.810 |
Why?
|
| Anxiety | 2 | 2016 | 195 | 0.800 |
Why?
|
| Body Mass Index | 3 | 2018 | 863 | 0.790 |
Why?
|
| Computers | 5 | 2018 | 22 | 0.780 |
Why?
|
| Asthma | 4 | 2010 | 262 | 0.780 |
Why?
|
| Fatty Acids | 3 | 2015 | 100 | 0.780 |
Why?
|
| Diagnosis, Computer-Assisted | 3 | 2019 | 52 | 0.760 |
Why?
|
| Ambulatory Care | 4 | 2019 | 111 | 0.730 |
Why?
|
| Child Health Services | 5 | 2014 | 24 | 0.720 |
Why?
|
| European Continental Ancestry Group | 3 | 2016 | 1076 | 0.720 |
Why?
|
| Postural Balance | 2 | 2014 | 142 | 0.710 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2017 | 158 | 0.710 |
Why?
|
| Medical Informatics | 4 | 2015 | 26 | 0.700 |
Why?
|
| Cells, Cultured | 13 | 2012 | 839 | 0.700 |
Why?
|
| Snoring | 2 | 2019 | 9 | 0.690 |
Why?
|
| Medicaid | 11 | 2019 | 101 | 0.680 |
Why?
|
| Health Status | 3 | 2017 | 356 | 0.680 |
Why?
|
| Follicle Stimulating Hormone | 8 | 2013 | 30 | 0.650 |
Why?
|
| United States | 23 | 2019 | 4068 | 0.640 |
Why?
|
| Logistic Models | 8 | 2018 | 743 | 0.640 |
Why?
|
| Internship and Residency | 3 | 2014 | 317 | 0.600 |
Why?
|
| Cyclic AMP | 4 | 2009 | 55 | 0.600 |
Why?
|
| Caregivers | 3 | 2019 | 114 | 0.600 |
Why?
|
| Family | 2 | 2017 | 112 | 0.590 |
Why?
|
| African Americans | 3 | 2016 | 1335 | 0.590 |
Why?
|
| Psychotherapy, Group | 2 | 2017 | 15 | 0.590 |
Why?
|
| Signal Transduction | 2 | 2015 | 727 | 0.590 |
Why?
|
| Office Visits | 2 | 2018 | 71 | 0.580 |
Why?
|
| Adult | 24 | 2019 | 9252 | 0.580 |
Why?
|
| Risk-Taking | 3 | 2016 | 96 | 0.570 |
Why?
|
| Prescription Drugs | 1 | 2018 | 19 | 0.560 |
Why?
|
| Patient Education as Topic | 2 | 2018 | 245 | 0.540 |
Why?
|
| Polysomnography | 1 | 2018 | 39 | 0.540 |
Why?
|
| Information Systems | 3 | 2015 | 9 | 0.540 |
Why?
|
| Risk Factors | 12 | 2019 | 3933 | 0.530 |
Why?
|
| Prevalence | 8 | 2018 | 955 | 0.530 |
Why?
|
| Oogenesis | 2 | 2015 | 6 | 0.530 |
Why?
|
| Programming Languages | 2 | 2015 | 4 | 0.520 |
Why?
|
| Nurse Practitioners | 1 | 2017 | 12 | 0.520 |
Why?
|
| Social Values | 1 | 2017 | 12 | 0.520 |
Why?
|
| Television | 2 | 2014 | 14 | 0.520 |
Why?
|
| Acetyl-CoA Carboxylase | 2 | 2015 | 22 | 0.510 |
Why?
|
| Decision Making | 7 | 2019 | 189 | 0.500 |
Why?
|
| Quality-Adjusted Life Years | 4 | 2011 | 33 | 0.490 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2016 | 83 | 0.490 |
Why?
|
| Pain | 1 | 2018 | 302 | 0.490 |
Why?
|
| Continuity of Patient Care | 4 | 2019 | 73 | 0.480 |
Why?
|
| Glycoproteins | 4 | 2013 | 34 | 0.480 |
Why?
|
| Young Adult | 9 | 2019 | 2643 | 0.470 |
Why?
|
| Spouse Abuse | 2 | 2013 | 6 | 0.470 |
Why?
|
| Glucose | 4 | 2006 | 160 | 0.470 |
Why?
|
| Clinical Alarms | 1 | 2015 | 5 | 0.470 |
Why?
|
| Expert Systems | 1 | 2015 | 4 | 0.470 |
Why?
|
| Cooperative Behavior | 3 | 2015 | 83 | 0.460 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2007 | 267 | 0.460 |
Why?
|
| Decision Trees | 7 | 2019 | 30 | 0.450 |
Why?
|
| Child Abuse | 2 | 2013 | 27 | 0.450 |
Why?
|
| Health Personnel | 5 | 2021 | 112 | 0.440 |
Why?
|
| Interprofessional Relations | 1 | 2015 | 42 | 0.440 |
Why?
|
| Rubella | 1 | 2015 | 1 | 0.440 |
Why?
|
| Mumps | 1 | 2015 | 2 | 0.440 |
Why?
|
| Measles | 1 | 2015 | 4 | 0.440 |
Why?
|
| Sodium Hypochlorite | 1 | 2014 | 2 | 0.440 |
Why?
|
| Mupirocin | 1 | 2014 | 3 | 0.440 |
Why?
|
| Hearing Loss | 2 | 2012 | 25 | 0.430 |
Why?
|
| Abscess | 1 | 2014 | 28 | 0.430 |
Why?
|
| Informed Consent | 1 | 2015 | 44 | 0.430 |
Why?
|
| Growth and Development | 1 | 2014 | 3 | 0.430 |
Why?
|
| Drainage | 1 | 2014 | 65 | 0.420 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 33 | 0.420 |
Why?
|
| Cell Nucleus | 1 | 2015 | 111 | 0.420 |
Why?
|
| Cross-Sectional Studies | 7 | 2019 | 1478 | 0.420 |
Why?
|
| Urogenital Abnormalities | 1 | 2014 | 3 | 0.420 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2013 | 100 | 0.410 |
Why?
|
| Staphylococcal Infections | 1 | 2014 | 78 | 0.410 |
Why?
|
| Pilot Projects | 8 | 2019 | 553 | 0.410 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2014 | 38 | 0.410 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2011 | 7 | 0.400 |
Why?
|
| Parental Consent | 1 | 2013 | 4 | 0.400 |
Why?
|
| Gastroesophageal Reflux | 1 | 2013 | 20 | 0.400 |
Why?
|
| Disease | 1 | 2013 | 5 | 0.400 |
Why?
|
| Spouses | 1 | 2013 | 13 | 0.390 |
Why?
|
| Medical Record Linkage | 2 | 2010 | 4 | 0.390 |
Why?
|
| Confidentiality | 3 | 2019 | 31 | 0.380 |
Why?
|
| Computational Biology | 1 | 2013 | 99 | 0.380 |
Why?
|
| Hospital Bed Capacity, under 100 | 1 | 2012 | 1 | 0.380 |
Why?
|
| Residence Characteristics | 1 | 2014 | 178 | 0.380 |
Why?
|
| Microtubules | 1 | 2012 | 18 | 0.380 |
Why?
|
| Genome, Human | 1 | 2013 | 130 | 0.370 |
Why?
|
| Hospitals, Rural | 1 | 2012 | 11 | 0.370 |
Why?
|
| Body Weight | 1 | 2014 | 323 | 0.370 |
Why?
|
| Books | 1 | 2012 | 3 | 0.370 |
Why?
|
| Epidermal Growth Factor | 2 | 2013 | 25 | 0.370 |
Why?
|
| Depression, Postpartum | 1 | 2012 | 10 | 0.370 |
Why?
|
| Office Automation | 1 | 2012 | 1 | 0.370 |
Why?
|
| Physicians' Offices | 1 | 2012 | 9 | 0.370 |
Why?
|
| Disease Management | 7 | 2013 | 129 | 0.370 |
Why?
|
| Policy Making | 1 | 2012 | 17 | 0.360 |
Why?
|
| Risk Assessment | 9 | 2019 | 1423 | 0.360 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2003 | 64 | 0.360 |
Why?
|
| Geriatric Assessment | 1 | 2014 | 335 | 0.360 |
Why?
|
| Physical Therapy Modalities | 1 | 2012 | 81 | 0.360 |
Why?
|
| Patient Selection | 1 | 2013 | 272 | 0.360 |
Why?
|
| Parent-Child Relations | 5 | 2013 | 45 | 0.350 |
Why?
|
| Hispanic Americans | 1 | 2016 | 772 | 0.350 |
Why?
|
| Adenosine | 3 | 2006 | 68 | 0.340 |
Why?
|
| Femoral Fractures | 1 | 2012 | 43 | 0.340 |
Why?
|
| Tuberculosis | 1 | 2011 | 17 | 0.340 |
Why?
|
| Sensitivity and Specificity | 7 | 2020 | 556 | 0.340 |
Why?
|
| Health Services Research | 1 | 2011 | 81 | 0.340 |
Why?
|
| Genome-Wide Association Study | 1 | 2013 | 543 | 0.340 |
Why?
|
| Dental Caries | 2 | 2013 | 21 | 0.330 |
Why?
|
| Ambulatory Care Information Systems | 4 | 2011 | 6 | 0.330 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 650 | 0.330 |
Why?
|
| Water | 1 | 2010 | 65 | 0.320 |
Why?
|
| G2 Phase | 1 | 2010 | 12 | 0.320 |
Why?
|
| Continental Population Groups | 1 | 2012 | 228 | 0.320 |
Why?
|
| Mental Health | 1 | 2011 | 111 | 0.320 |
Why?
|
| Cell Division | 1 | 2010 | 92 | 0.320 |
Why?
|
| Information Services | 1 | 2010 | 11 | 0.310 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 821 | 0.310 |
Why?
|
| Immunization Schedule | 1 | 2009 | 25 | 0.310 |
Why?
|
| Curriculum | 1 | 2011 | 203 | 0.300 |
Why?
|
| Bucladesine | 5 | 2011 | 6 | 0.300 |
Why?
|
| Purines | 3 | 2004 | 21 | 0.300 |
Why?
|
| Tuberculin Test | 1 | 2009 | 2 | 0.300 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2009 | 2 | 0.300 |
Why?
|
| Antitubercular Agents | 1 | 2009 | 7 | 0.290 |
Why?
|
| Isoniazid | 1 | 2009 | 4 | 0.290 |
Why?
|
| Age Factors | 4 | 2018 | 1178 | 0.290 |
Why?
|
| Directive Counseling | 1 | 2008 | 19 | 0.290 |
Why?
|
| Obesity | 2 | 2014 | 1111 | 0.280 |
Why?
|
| Enzyme Activation | 4 | 2013 | 138 | 0.270 |
Why?
|
| Internet | 1 | 2009 | 202 | 0.270 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 116 | 0.270 |
Why?
|
| Outpatients | 2 | 2019 | 57 | 0.270 |
Why?
|
| Sorbitol | 2 | 2005 | 2 | 0.270 |
Why?
|
| Retrospective Studies | 6 | 2019 | 3609 | 0.260 |
Why?
|
| Enzyme Inhibitors | 4 | 2011 | 174 | 0.260 |
Why?
|
| Glutamine | 2 | 2006 | 10 | 0.260 |
Why?
|
| Software | 7 | 2013 | 124 | 0.260 |
Why?
|
| Prospective Studies | 6 | 2018 | 2315 | 0.260 |
Why?
|
| Rats | 1 | 2011 | 1895 | 0.260 |
Why?
|
| Hypoxanthine | 4 | 2011 | 5 | 0.260 |
Why?
|
| Physician-Patient Relations | 3 | 2018 | 179 | 0.260 |
Why?
|
| Middle Aged | 12 | 2019 | 11837 | 0.250 |
Why?
|
| Blotting, Western | 4 | 2012 | 299 | 0.250 |
Why?
|
| Heat Stress Disorders | 1 | 2006 | 9 | 0.250 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2006 | 41 | 0.250 |
Why?
|
| Celiac Disease | 1 | 2006 | 4 | 0.250 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 772 | 0.250 |
Why?
|
| Emigrants and Immigrants | 1 | 2009 | 198 | 0.240 |
Why?
|
| Down Syndrome | 1 | 2006 | 15 | 0.240 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2006 | 4 | 0.240 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2006 | 28 | 0.240 |
Why?
|
| Fever of Unknown Origin | 1 | 2006 | 10 | 0.240 |
Why?
|
| Cariostatic Agents | 1 | 2006 | 4 | 0.240 |
Why?
|
| Fluorides, Topical | 1 | 2006 | 6 | 0.240 |
Why?
|
| Smoking Cessation | 1 | 2008 | 211 | 0.240 |
Why?
|
| Social Class | 3 | 2018 | 90 | 0.240 |
Why?
|
| Cyclic AMP-Dependent Protein Kinase Catalytic Subunits | 1 | 2005 | 1 | 0.230 |
Why?
|
| Qualitative Research | 3 | 2017 | 179 | 0.230 |
Why?
|
| Stress, Physiological | 1 | 2005 | 57 | 0.230 |
Why?
|
| Physical Examination | 2 | 2018 | 83 | 0.230 |
Why?
|
| Choice Behavior | 1 | 2006 | 84 | 0.220 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2005 | 11 | 0.220 |
Why?
|
| Forms and Records Control | 1 | 2005 | 8 | 0.220 |
Why?
|
| Health Care Costs | 3 | 2013 | 122 | 0.220 |
Why?
|
| Health Services | 2 | 2010 | 40 | 0.220 |
Why?
|
| Blood Glucose | 1 | 2007 | 484 | 0.220 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2005 | 90 | 0.210 |
Why?
|
| Chronic Disease | 5 | 2010 | 413 | 0.210 |
Why?
|
| Incidence | 3 | 2014 | 1241 | 0.210 |
Why?
|
| Likelihood Functions | 3 | 2020 | 50 | 0.210 |
Why?
|
| Oxidation-Reduction | 3 | 2013 | 274 | 0.210 |
Why?
|
| Models, Biological | 1 | 2006 | 408 | 0.200 |
Why?
|
| Video Recording | 2 | 2019 | 61 | 0.200 |
Why?
|
| Health Status Indicators | 1 | 2003 | 69 | 0.200 |
Why?
|
| Data Collection | 2 | 2014 | 171 | 0.200 |
Why?
|
| Patient-Centered Care | 2 | 2014 | 75 | 0.190 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 3893 | 0.190 |
Why?
|
| Pregnancy Outcome | 2 | 2019 | 86 | 0.190 |
Why?
|
| Odds Ratio | 3 | 2019 | 455 | 0.180 |
Why?
|
| Pyruvic Acid | 1 | 2002 | 6 | 0.180 |
Why?
|
| Longitudinal Studies | 2 | 2014 | 759 | 0.180 |
Why?
|
| Immunization | 2 | 2012 | 38 | 0.180 |
Why?
|
| Physician's Role | 2 | 2016 | 41 | 0.180 |
Why?
|
| Anti-Bacterial Agents | 3 | 2014 | 324 | 0.180 |
Why?
|
| Cesarean Section | 2 | 2019 | 114 | 0.180 |
Why?
|
| Patient Discharge | 2 | 2014 | 204 | 0.180 |
Why?
|
| Comorbidity | 2 | 2018 | 563 | 0.180 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2002 | 3 | 0.180 |
Why?
|
| Risk | 2 | 2017 | 305 | 0.180 |
Why?
|
| Malonyl Coenzyme A | 2 | 2013 | 2 | 0.180 |
Why?
|
| Epoxy Compounds | 2 | 2013 | 9 | 0.180 |
Why?
|
| Socioeconomic Factors | 3 | 2019 | 388 | 0.170 |
Why?
|
| Point-of-Care Systems | 1 | 2002 | 44 | 0.170 |
Why?
|
| Feasibility Studies | 3 | 2013 | 309 | 0.170 |
Why?
|
| Aged | 7 | 2017 | 10249 | 0.170 |
Why?
|
| Pregnancy | 7 | 2019 | 960 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2020 | 1437 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 544 | 0.160 |
Why?
|
| Analysis of Variance | 3 | 2019 | 471 | 0.160 |
Why?
|
| Health Literacy | 2 | 2019 | 27 | 0.160 |
Why?
|
| Hypospadias | 1 | 2019 | 10 | 0.150 |
Why?
|
| Mothers | 2 | 2014 | 74 | 0.150 |
Why?
|
| Information Seeking Behavior | 1 | 2019 | 9 | 0.150 |
Why?
|
| Pregnancy, Unplanned | 1 | 2019 | 2 | 0.150 |
Why?
|
| Appointments and Schedules | 1 | 2019 | 21 | 0.150 |
Why?
|
| Computers, Handheld | 1 | 2019 | 15 | 0.150 |
Why?
|
| Prosthesis Implantation | 1 | 2019 | 36 | 0.150 |
Why?
|
| Infant Mortality | 1 | 2019 | 21 | 0.150 |
Why?
|
| Perception | 1 | 2020 | 99 | 0.150 |
Why?
|
| Sex Distribution | 2 | 2018 | 174 | 0.150 |
Why?
|
| Patient Preference | 1 | 2019 | 48 | 0.150 |
Why?
|
| Ureteroscopy | 1 | 2019 | 6 | 0.150 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 2238 | 0.150 |
Why?
|
| Lithotripsy | 1 | 2019 | 12 | 0.150 |
Why?
|
| Ureteral Calculi | 1 | 2019 | 7 | 0.150 |
Why?
|
| Thinness | 1 | 2019 | 32 | 0.150 |
Why?
|
| Quality of Life | 3 | 2012 | 968 | 0.140 |
Why?
|
| Treatment Outcome | 3 | 2015 | 3408 | 0.140 |
Why?
|
| Time Factors | 5 | 2019 | 2203 | 0.140 |
Why?
|
| Systems Integration | 3 | 2010 | 11 | 0.140 |
Why?
|
| Paternal Behavior | 1 | 2018 | 1 | 0.140 |
Why?
|
| Prescriptions | 1 | 2018 | 15 | 0.140 |
Why?
|
| Fathers | 1 | 2018 | 12 | 0.140 |
Why?
|
| Cluster Analysis | 1 | 2018 | 120 | 0.140 |
Why?
|
| Adolescent Behavior | 1 | 2019 | 64 | 0.140 |
Why?
|
| Premature Birth | 1 | 2019 | 73 | 0.140 |
Why?
|
| Seasons | 1 | 2018 | 74 | 0.140 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 109 | 0.140 |
Why?
|
| Clinical Competence | 2 | 2011 | 329 | 0.140 |
Why?
|
| Postpartum Period | 1 | 2018 | 36 | 0.140 |
Why?
|
| Home Care Services | 1 | 2019 | 51 | 0.140 |
Why?
|
| Adolescent Medicine | 1 | 2018 | 1 | 0.140 |
Why?
|
| Age Distribution | 1 | 2018 | 194 | 0.140 |
Why?
|
| Diphtheria | 1 | 2018 | 1 | 0.140 |
Why?
|
| Tetanus | 1 | 2018 | 2 | 0.140 |
Why?
|
| Adolescent Health Services | 1 | 2018 | 12 | 0.140 |
Why?
|
| Meningococcal Infections | 1 | 2018 | 7 | 0.140 |
Why?
|
| Whooping Cough | 1 | 2018 | 10 | 0.140 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2018 | 7 | 0.140 |
Why?
|
| Meningococcal Vaccines | 1 | 2018 | 10 | 0.140 |
Why?
|
| Vaccines, Conjugate | 1 | 2018 | 17 | 0.140 |
Why?
|
| Insurance Coverage | 1 | 2018 | 80 | 0.130 |
Why?
|
| Hospitalization | 2 | 2012 | 475 | 0.130 |
Why?
|
| Language | 1 | 2018 | 35 | 0.130 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 2 | 2011 | 3 | 0.130 |
Why?
|
| Suicide | 1 | 2017 | 19 | 0.130 |
Why?
|
| Stents | 1 | 2019 | 159 | 0.130 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2017 | 41 | 0.130 |
Why?
|
| Fetal Viability | 1 | 2017 | 2 | 0.130 |
Why?
|
| Pregnant Women | 1 | 2017 | 6 | 0.130 |
Why?
|
| Hypoglycemic Agents | 2 | 2012 | 186 | 0.130 |
Why?
|
| Unsafe Sex | 1 | 2016 | 23 | 0.120 |
Why?
|
| Data Mining | 2 | 2013 | 14 | 0.120 |
Why?
|
| Focus Groups | 2 | 2015 | 123 | 0.120 |
Why?
|
| Area Under Curve | 2 | 2013 | 90 | 0.120 |
Why?
|
| Counseling | 1 | 2017 | 94 | 0.120 |
Why?
|
| Attitude | 2 | 2013 | 37 | 0.120 |
Why?
|
| Resuscitation | 1 | 2017 | 66 | 0.120 |
Why?
|
| Prenatal Care | 1 | 2017 | 54 | 0.120 |
Why?
|
| Consensus | 1 | 2016 | 87 | 0.120 |
Why?
|
| Vidarabine | 2 | 2006 | 6 | 0.120 |
Why?
|
| Antipsychotic Agents | 1 | 2016 | 30 | 0.120 |
Why?
|
| Reimbursement Mechanisms | 2 | 2013 | 12 | 0.120 |
Why?
|
| Computer Simulation | 2 | 2013 | 251 | 0.110 |
Why?
|
| Adenosine Monophosphate | 2 | 2008 | 7 | 0.110 |
Why?
|
| Macrolides | 1 | 2015 | 5 | 0.110 |
Why?
|
| Chorionic Gonadotropin | 2 | 2007 | 6 | 0.110 |
Why?
|
| Morpholines | 1 | 2015 | 47 | 0.110 |
Why?
|
| Costs and Cost Analysis | 3 | 2019 | 106 | 0.110 |
Why?
|
| Disinfectants | 1 | 2014 | 4 | 0.110 |
Why?
|
| Baths | 1 | 2014 | 6 | 0.110 |
Why?
|
| Culture Media | 2 | 2006 | 48 | 0.110 |
Why?
|
| Diffusion of Innovation | 3 | 2010 | 33 | 0.110 |
Why?
|
| Administration, Intranasal | 1 | 2014 | 35 | 0.110 |
Why?
|
| Phosphorylation | 2 | 2005 | 250 | 0.110 |
Why?
|
| Mice, Inbred Strains | 2 | 2006 | 55 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2019 | 1839 | 0.110 |
Why?
|
| Growth Charts | 1 | 2014 | 4 | 0.110 |
Why?
|
| Community Medicine | 1 | 2014 | 2 | 0.110 |
Why?
|
| Teaching Rounds | 1 | 2014 | 5 | 0.110 |
Why?
|
| Probability | 2 | 2013 | 155 | 0.110 |
Why?
|
| Pentostatin | 2 | 2006 | 3 | 0.110 |
Why?
|
| Health Policy | 2 | 2012 | 89 | 0.110 |
Why?
|
| Piperidines | 1 | 2015 | 137 | 0.100 |
Why?
|
| Infant Behavior | 1 | 2014 | 8 | 0.100 |
Why?
|
| Community Health Services | 1 | 2014 | 47 | 0.100 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2014 | 4 | 0.100 |
Why?
|
| Hospitals, Pediatric | 1 | 2014 | 48 | 0.100 |
Why?
|
| Milk | 1 | 2014 | 13 | 0.100 |
Why?
|
| Esophageal pH Monitoring | 1 | 2013 | 3 | 0.100 |
Why?
|
| Regression Analysis | 2 | 2012 | 273 | 0.100 |
Why?
|
| Ambulatory Care Facilities | 1 | 2014 | 83 | 0.100 |
Why?
|
| Needs Assessment | 1 | 2014 | 78 | 0.100 |
Why?
|
| Psychological Tests | 1 | 2013 | 31 | 0.100 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2013 | 21 | 0.100 |
Why?
|
| Blood Specimen Collection | 1 | 2013 | 2 | 0.100 |
Why?
|
| Aminophenols | 1 | 2013 | 1 | 0.100 |
Why?
|
| Thioglycolates | 1 | 2013 | 1 | 0.100 |
Why?
|
| Hydrazones | 1 | 2013 | 3 | 0.100 |
Why?
|
| Acyl Coenzyme A | 1 | 2013 | 5 | 0.100 |
Why?
|
| Wounds and Injuries | 1 | 2016 | 241 | 0.100 |
Why?
|
| Fluorides | 1 | 2013 | 5 | 0.100 |
Why?
|
| Communication Disorders | 1 | 2013 | 1 | 0.100 |
Why?
|
| Gastric Bypass | 1 | 2013 | 29 | 0.100 |
Why?
|
| Hospitals, University | 1 | 2013 | 27 | 0.100 |
Why?
|
| Problem Solving | 1 | 2013 | 26 | 0.100 |
Why?
|
| Urban Population | 1 | 2014 | 91 | 0.100 |
Why?
|
| Confidence Intervals | 1 | 2013 | 141 | 0.100 |
Why?
|
| Calcimycin | 1 | 2013 | 8 | 0.100 |
Why?
|
| Psychotropic Drugs | 1 | 2013 | 12 | 0.100 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 161 | 0.100 |
Why?
|
| Databases, Genetic | 1 | 2013 | 39 | 0.100 |
Why?
|
| Mitochondria | 1 | 2015 | 211 | 0.100 |
Why?
|
| Failure to Thrive | 1 | 2013 | 1 | 0.100 |
Why?
|
| Linear Models | 1 | 2014 | 426 | 0.100 |
Why?
|
| Carnitine | 2 | 2011 | 14 | 0.100 |
Why?
|
| ROC Curve | 1 | 2013 | 169 | 0.100 |
Why?
|
| Ovulation | 2 | 2003 | 8 | 0.100 |
Why?
|
| Cytoskeleton | 1 | 2012 | 20 | 0.100 |
Why?
|
| New South Wales | 1 | 2012 | 1 | 0.090 |
Why?
|
| Cell Cycle Proteins | 1 | 2013 | 52 | 0.090 |
Why?
|
| Poverty | 1 | 2013 | 105 | 0.090 |
Why?
|
| Immunity, Herd | 1 | 2012 | 6 | 0.090 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 95 | 0.090 |
Why?
|
| Patient Admission | 1 | 2013 | 54 | 0.090 |
Why?
|
| Program Development | 3 | 2010 | 93 | 0.090 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 167 | 0.090 |
Why?
|
| Hospitals, Urban | 1 | 2012 | 12 | 0.090 |
Why?
|
| Knowledge Bases | 1 | 2012 | 4 | 0.090 |
Why?
|
| Education | 1 | 2012 | 31 | 0.090 |
Why?
|
| Diabetes Mellitus | 2 | 2005 | 390 | 0.090 |
Why?
|
| Child Behavior | 1 | 2012 | 25 | 0.090 |
Why?
|
| Cell Differentiation | 2 | 2006 | 461 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 854 | 0.090 |
Why?
|
| Milrinone | 1 | 2011 | 2 | 0.090 |
Why?
|
| Life Style | 1 | 2014 | 394 | 0.090 |
Why?
|
| Cyclic GMP | 1 | 2011 | 23 | 0.090 |
Why?
|
| Length of Stay | 1 | 2013 | 321 | 0.090 |
Why?
|
| Ultrasonography | 1 | 2014 | 393 | 0.090 |
Why?
|
| Phenotype | 1 | 2013 | 622 | 0.090 |
Why?
|
| Patient Compliance | 2 | 2010 | 206 | 0.090 |
Why?
|
| Personal Satisfaction | 1 | 2011 | 29 | 0.090 |
Why?
|
| Mental Competency | 1 | 2011 | 11 | 0.080 |
Why?
|
| Cell Separation | 1 | 2011 | 89 | 0.080 |
Why?
|
| Metabolic Diseases | 1 | 2011 | 17 | 0.080 |
Why?
|
| Information Management | 1 | 2010 | 1 | 0.080 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2011 | 40 | 0.080 |
Why?
|
| Horses | 1 | 2010 | 18 | 0.080 |
Why?
|
| Telemedicine | 2 | 2010 | 122 | 0.080 |
Why?
|
| Enzyme Activators | 1 | 2010 | 8 | 0.080 |
Why?
|
| Ethanol | 1 | 2013 | 195 | 0.080 |
Why?
|
| Health Records, Personal | 1 | 2010 | 11 | 0.080 |
Why?
|
| Rodentia | 1 | 2010 | 9 | 0.080 |
Why?
|
| Health Promotion | 2 | 2010 | 242 | 0.080 |
Why?
|
| Health Services Administration | 1 | 2010 | 3 | 0.080 |
Why?
|
| Education, Medical, Graduate | 1 | 2011 | 130 | 0.080 |
Why?
|
| Pyrazoles | 1 | 2010 | 77 | 0.080 |
Why?
|
| Narration | 1 | 2010 | 16 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 500 | 0.080 |
Why?
|
| Vocabulary, Controlled | 1 | 2010 | 6 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2010 | 77 | 0.080 |
Why?
|
| Patient Satisfaction | 1 | 2011 | 230 | 0.080 |
Why?
|
| Vaccines | 1 | 2009 | 13 | 0.080 |
Why?
|
| 4-Butyrolactone | 1 | 2009 | 1 | 0.080 |
Why?
|
| Cerulenin | 1 | 2009 | 3 | 0.080 |
Why?
|
| Zona Pellucida | 1 | 2009 | 1 | 0.080 |
Why?
|
| Interviews as Topic | 2 | 2016 | 194 | 0.080 |
Why?
|
| Palmitic Acid | 1 | 2009 | 9 | 0.080 |
Why?
|
| Periodicity | 1 | 2009 | 11 | 0.080 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2009 | 9 | 0.080 |
Why?
|
| Research Design | 1 | 2011 | 316 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2010 | 187 | 0.080 |
Why?
|
| Telephone | 2 | 2010 | 61 | 0.070 |
Why?
|
| Information Dissemination | 1 | 2010 | 52 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 1050 | 0.070 |
Why?
|
| Blood Cell Count | 2 | 2006 | 28 | 0.070 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 70 | 0.070 |
Why?
|
| Blindness | 1 | 2009 | 13 | 0.070 |
Why?
|
| Community Networks | 1 | 2009 | 22 | 0.070 |
Why?
|
| Gastroenteritis | 1 | 2009 | 11 | 0.070 |
Why?
|
| Russia | 1 | 2009 | 4 | 0.070 |
Why?
|
| Otitis Media | 1 | 2009 | 24 | 0.070 |
Why?
|
| Adoption | 1 | 2009 | 2 | 0.070 |
Why?
|
| Rifampin | 1 | 2009 | 7 | 0.070 |
Why?
|
| Hypersensitivity | 1 | 2009 | 24 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2011 | 897 | 0.070 |
Why?
|
| Sex Factors | 2 | 2017 | 656 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 544 | 0.070 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2009 | 78 | 0.070 |
Why?
|
| Drug Costs | 1 | 2009 | 46 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2009 | 193 | 0.070 |
Why?
|
| Heart Failure | 2 | 2005 | 728 | 0.070 |
Why?
|
| Secondary Prevention | 1 | 2009 | 73 | 0.070 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2011 | 40 | 0.070 |
Why?
|
| Pattern Recognition, Automated | 1 | 2008 | 36 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 276 | 0.070 |
Why?
|
| Cerebral Palsy | 1 | 2009 | 72 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 292 | 0.070 |
Why?
|
| Tyrphostins | 1 | 2008 | 1 | 0.070 |
Why?
|
| Epilepsy | 1 | 2009 | 79 | 0.070 |
Why?
|
| North Carolina | 2 | 2019 | 1300 | 0.070 |
Why?
|
| Paper | 2 | 2005 | 4 | 0.070 |
Why?
|
| Patient Access to Records | 1 | 2007 | 4 | 0.070 |
Why?
|
| Quinazolines | 1 | 2008 | 35 | 0.070 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2007 | 2 | 0.070 |
Why?
|
| Protein Kinase C | 1 | 2008 | 43 | 0.070 |
Why?
|
| Models, Theoretical | 2 | 2006 | 139 | 0.070 |
Why?
|
| Battered Women | 1 | 2007 | 2 | 0.070 |
Why?
|
| Medical Records | 1 | 2007 | 75 | 0.070 |
Why?
|
| Professional-Patient Relations | 1 | 2007 | 23 | 0.060 |
Why?
|
| Peptides | 1 | 2008 | 127 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2006 | 1 | 0.060 |
Why?
|
| Trust | 1 | 2007 | 43 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 14 | 1 | 2006 | 2 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 2006 | 5 | 0.060 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2006 | 20 | 0.060 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2007 | 23 | 0.060 |
Why?
|
| Halogens | 1 | 2006 | 1 | 0.060 |
Why?
|
| Metaphase | 1 | 2006 | 2 | 0.060 |
Why?
|
| Cost Savings | 2 | 2019 | 34 | 0.060 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2006 | 14 | 0.060 |
Why?
|
| Monitoring, Physiologic | 1 | 2007 | 77 | 0.060 |
Why?
|
| Disease Susceptibility | 1 | 2006 | 61 | 0.060 |
Why?
|
| Meningitis, Pneumococcal | 1 | 2006 | 1 | 0.060 |
Why?
|
| Blood | 1 | 2006 | 13 | 0.060 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2006 | 34 | 0.060 |
Why?
|
| Kinetics | 1 | 2006 | 250 | 0.060 |
Why?
|
| Biomedical Technology | 1 | 2006 | 5 | 0.060 |
Why?
|
| Microinjections | 1 | 2006 | 39 | 0.060 |
Why?
|
| Teratogens | 1 | 2005 | 2 | 0.060 |
Why?
|
| Pneumococcal Vaccines | 1 | 2006 | 28 | 0.060 |
Why?
|
| Vitamin K 3 | 1 | 2005 | 7 | 0.060 |
Why?
|
| Arsenites | 1 | 2005 | 4 | 0.060 |
Why?
|
| Cathartics | 1 | 2005 | 5 | 0.060 |
Why?
|
| Mass Spectrometry | 1 | 2006 | 98 | 0.060 |
Why?
|
| Antimetabolites | 1 | 2005 | 11 | 0.060 |
Why?
|
| Coculture Techniques | 1 | 2006 | 78 | 0.060 |
Why?
|
| Thiazolidinediones | 1 | 2006 | 46 | 0.060 |
Why?
|
| Bacteremia | 1 | 2006 | 66 | 0.060 |
Why?
|
| Vitamins | 1 | 2005 | 70 | 0.060 |
Why?
|
| Okadaic Acid | 1 | 2005 | 6 | 0.060 |
Why?
|
| Butadienes | 1 | 2005 | 9 | 0.060 |
Why?
|
| Pit and Fissure Sealants | 1 | 2005 | 1 | 0.060 |
Why?
|
| Practice Management | 1 | 2005 | 1 | 0.060 |
Why?
|
| Flavonoids | 1 | 2005 | 20 | 0.060 |
Why?
|
| Nitriles | 1 | 2005 | 24 | 0.050 |
Why?
|
| Medicare | 1 | 2006 | 218 | 0.050 |
Why?
|
| Health Education | 1 | 2005 | 149 | 0.050 |
Why?
|
| Organizational Innovation | 1 | 2005 | 33 | 0.050 |
Why?
|
| Medical Errors | 1 | 2005 | 34 | 0.050 |
Why?
|
| Aldehyde Reductase | 1 | 2004 | 3 | 0.050 |
Why?
|
| Scintillation Counting | 1 | 2004 | 3 | 0.050 |
Why?
|
| Carbon Isotopes | 1 | 2004 | 10 | 0.050 |
Why?
|
| Tritium | 1 | 2004 | 19 | 0.050 |
Why?
|
| Crosses, Genetic | 1 | 2004 | 21 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2019 | 367 | 0.050 |
Why?
|
| Child Welfare | 1 | 2004 | 18 | 0.050 |
Why?
|
| Antidepressive Agents | 2 | 2019 | 73 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 716 | 0.050 |
Why?
|
| Survival Rate | 1 | 2006 | 892 | 0.050 |
Why?
|
| Mammography | 1 | 2003 | 41 | 0.050 |
Why?
|
| Erythromycin | 1 | 2003 | 8 | 0.050 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2003 | 4 | 0.050 |
Why?
|
| Chlamydia trachomatis | 1 | 2003 | 7 | 0.050 |
Why?
|
| Matched-Pair Analysis | 1 | 2003 | 11 | 0.050 |
Why?
|
| Chlamydia Infections | 1 | 2003 | 9 | 0.050 |
Why?
|
| Cell Communication | 1 | 2003 | 37 | 0.050 |
Why?
|
| Educational Status | 1 | 2003 | 167 | 0.050 |
Why?
|
| Delivery, Obstetric | 2 | 2019 | 53 | 0.050 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2003 | 38 | 0.050 |
Why?
|
| Medical History Taking | 1 | 2003 | 39 | 0.050 |
Why?
|
| Hypoxanthines | 1 | 2002 | 1 | 0.050 |
Why?
|
| Blastocyst | 1 | 2002 | 8 | 0.050 |
Why?
|
| Embryonic and Fetal Development | 1 | 2002 | 11 | 0.050 |
Why?
|
| Cell Culture Techniques | 1 | 2003 | 170 | 0.050 |
Why?
|
| Osmolar Concentration | 1 | 2002 | 23 | 0.050 |
Why?
|
| Mice, Inbred NOD | 1 | 2002 | 26 | 0.050 |
Why?
|
| Epithelial Cells | 1 | 2003 | 132 | 0.050 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2002 | 17 | 0.050 |
Why?
|
| Labor, Induced | 1 | 2002 | 17 | 0.040 |
Why?
|
| Fibronectins | 1 | 2002 | 39 | 0.040 |
Why?
|
| Environment | 1 | 2002 | 47 | 0.040 |
Why?
|
| Ovary | 1 | 2002 | 66 | 0.040 |
Why?
|
| DNA | 1 | 2002 | 223 | 0.040 |
Why?
|
| Insulin | 1 | 2002 | 359 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2004 | 1081 | 0.040 |
Why?
|
| Term Birth | 1 | 2019 | 4 | 0.040 |
Why?
|
| Parturition | 1 | 2019 | 9 | 0.040 |
Why?
|
| Abortion, Induced | 1 | 2019 | 7 | 0.040 |
Why?
|
| Psychotherapy | 1 | 2019 | 20 | 0.040 |
Why?
|
| Health Planning | 2 | 2010 | 6 | 0.040 |
Why?
|
| Father-Child Relations | 1 | 2018 | 2 | 0.040 |
Why?
|
| Group Processes | 1 | 2018 | 12 | 0.030 |
Why?
|
| Suicide, Attempted | 1 | 2017 | 33 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2003 | 763 | 0.030 |
Why?
|
| Automation | 1 | 2017 | 28 | 0.030 |
Why?
|
| Reproductive History | 1 | 2017 | 5 | 0.030 |
Why?
|
| Maternal Age | 1 | 2017 | 13 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 43 | 0.030 |
Why?
|
| Registries | 2 | 2009 | 294 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2017 | 184 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 100 | 0.030 |
Why?
|
| Sexual Behavior | 1 | 2016 | 130 | 0.030 |
Why?
|
| Prognosis | 1 | 2019 | 1529 | 0.030 |
Why?
|
| Electroencephalography | 1 | 2014 | 75 | 0.030 |
Why?
|
| Iron, Dietary | 1 | 2014 | 8 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2014 | 171 | 0.020 |
Why?
|
| Obstetrics | 1 | 2013 | 25 | 0.020 |
Why?
|
| Patient Participation | 1 | 2014 | 90 | 0.020 |
Why?
|
| Social Responsibility | 1 | 2012 | 14 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 212 | 0.020 |
Why?
|
| Cefixime | 1 | 2011 | 4 | 0.020 |
Why?
|
| Motivation | 1 | 2012 | 121 | 0.020 |
Why?
|
| Pyelonephritis | 1 | 2011 | 9 | 0.020 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2011 | 22 | 0.020 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2011 | 44 | 0.020 |
Why?
|
| Fever | 1 | 2011 | 59 | 0.020 |
Why?
|
| International Cooperation | 1 | 2011 | 31 | 0.020 |
Why?
|
| Database Management Systems | 1 | 2010 | 11 | 0.020 |
Why?
|
| Amino Acids | 1 | 2011 | 52 | 0.020 |
Why?
|
| Recurrence | 1 | 2011 | 286 | 0.020 |
Why?
|
| Reference Values | 1 | 2011 | 238 | 0.020 |
Why?
|
| Radiography | 1 | 2011 | 358 | 0.020 |
Why?
|
| Disabled Persons | 1 | 2010 | 100 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 1211 | 0.020 |
Why?
|
| Urinary Bladder | 1 | 2011 | 320 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2010 | 160 | 0.020 |
Why?
|
| Truth Disclosure | 1 | 2007 | 14 | 0.020 |
Why?
|
| Social Environment | 1 | 2007 | 75 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2007 | 39 | 0.020 |
Why?
|
| Erythrocyte Indices | 1 | 2006 | 4 | 0.010 |
Why?
|
| Hematocrit | 1 | 2006 | 20 | 0.010 |
Why?
|
| Physicians, Family | 1 | 2006 | 14 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2006 | 45 | 0.010 |
Why?
|
| Models, Econometric | 1 | 2005 | 8 | 0.010 |
Why?
|
| State Health Plans | 1 | 2005 | 4 | 0.010 |
Why?
|
| Molar | 1 | 2005 | 4 | 0.010 |
Why?
|
| Dental Restoration, Permanent | 1 | 2005 | 4 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2006 | 153 | 0.010 |
Why?
|
| Markov Chains | 1 | 2005 | 31 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2006 | 148 | 0.010 |
Why?
|
| Conjunctivitis, Bacterial | 1 | 2003 | 1 | 0.010 |
Why?
|
| Pyloric Stenosis | 1 | 2003 | 4 | 0.010 |
Why?
|
| Health Behavior | 1 | 2005 | 213 | 0.010 |
Why?
|
| Pneumonia, Bacterial | 1 | 2003 | 33 | 0.010 |
Why?
|
| Parity | 1 | 2002 | 19 | 0.010 |
Why?
|
| Geographic Information Systems | 1 | 2002 | 13 | 0.010 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2002 | 19 | 0.010 |
Why?
|